Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
FP04 - Immunotherapy (Phase II/III Trials)
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 4
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
00:00 - 00:00 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
- Presentations: 14
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P60.12 - Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC
00:00 - 00:00 | Presenter: Monica Motwani
- Abstract
Loading...
-
+
P70 - Tumor Biology and Systems Biology: Basic and Translational Science - Omics Analysis of Lung Cancer
- Type: Posters
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
- Presentations: 20
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P70.09 - NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer
00:00 - 00:00 | Author(s): Bin-bin Song
- Abstract
Loading... -
+
P70.11 - Prevalence and Clinicopathological Characteristics of ARID1A Mutations in East Asian Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Author(s): Chun-wei Xu
- Abstract
Loading... -
+
P70.13 - Different Types of ERBB3 Mutations in Chinese Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Qian Wang
- Abstract
Loading... -
+
P70.14 - PRKDC Mutations Recurrently Found in Non-Small Cell Lung Cancer in East Asian Patients
00:00 - 00:00 | Author(s): Fen Lan
- Abstract
Loading... -
+
P70.15 - Mutational Subtypes and Prognosis of East Asian Non-Small-Cell Lung Cancer Harboring NF2 Mutations
00:00 - 00:00 | Author(s): Liyun Miao
- Abstract
Loading... -
+
P70.16 - Epidemiological Study of FGFR3 Mutations Among Non-Small Cell Lung Cancer Patients in China
00:00 - 00:00 | Author(s): You-cai Zhu
- Abstract
Loading... -
+
P70.17 - Molecular Characteristics and Prognosis TERT Mutations in East Asian Non-Small-Cell Lung Cancer Patients
00:00 - 00:00 | Author(s): Wen-bin Gao
- Abstract
Loading... -
+
P70.18 - Distribution of GNAS Mutations in Chinese Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Author(s): Lei Lai
- Abstract
Loading... -
+
P70.19 - Clinicopathologic Characteristics of Patients With LRP1B Mutations in Chinese Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Author(s): Gen-hua Yu
- Abstract
Loading...
-
+
MA02 - RET and Novel Combinations of Osimertinib
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 09:30 - 10:30, Program Auditorium
-
+
MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
09:30 - 09:35 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 5
- Moderators:Rina Hui
- Coordinates: 9/09/2021, 09:30 - 10:30, Program Auditorium
-
+
OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
09:30 - 09:40 | Presenter: David Carbone
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- Type: Workshop
- Track: N.A.
- Presentations: 9
- Moderators:Caicun Zhou
- Coordinates: 9/11/2021, 22:15 - 23:45, Program Auditorium
-
+
WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
22:53 - 23:03 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
23:13 - 23:23 | Presenter: Shun Lu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 6
- Moderators:Helena A Yu
- Coordinates: 9/12/2021, 18:45 - 19:45, Program Auditorium
-
+
OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
19:15 - 19:25 | Presenter: D. Ross Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
